Anti-TNF's for postoperative recurrence in Crohn's disease: The if's and how's

D. Sorrentino, A. Paviotti, G. Fiorino

Research output: Contribution to journalArticlepeer-review


Recurrence of Crohn's disease (CD) is extremely frequent after surgery and its prevention remains a fundamental problem in the medical management of these patients. As of today, none of the medications traditionally used to treat the spontaneous disease (i.e. mesalamine, steroids, immunosuppressives and antibiotics) has shown a clear benefit. Recent data, coming from our center and from a small RCT do indicate that infliximab is extremely effective in preventing this complication in the large majority of patients. While additional, larger studies may be desirable, the strength and consistency of the available data suggest that future trials may merely confirm these observations. A number of issues however remain to be solved and include the long term strategy in patients treated for years with infliximab, whether treating early endoscopic lesions may be as effective as preventing them and whether immuno-soppressives should be used together with infliximab. A thorough understanding of the mechanisms by which infliximab appears so effective in the postoperative setting may provide us with essential information regarding patients' management and, ultimately, highlight the molecular mechanisms at the very basis of Crohn's disease.

Original languageEnglish
Pages (from-to)219-226
Number of pages8
JournalCurrent Drug Targets
Issue number2
Publication statusPublished - Feb 2010

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine


Dive into the research topics of 'Anti-TNF's for postoperative recurrence in Crohn's disease: The if's and how's'. Together they form a unique fingerprint.

Cite this